Nanobiotix Phase 2 Lung Cancer Trial Shows 85.7% Response Rate

Nanobiotix presented Part 1 data from its randomized Phase 2 CONVERGE study at the 2026 ESTRO meeting, advancing clinical visibility for JNJ-1900 (NBTXR3). The update is tied to a Johnson & Johnson-sponsored trial and underscores continued development of the nanoparticle-based cancer therapy. The release is positive but early-stage and unlikely to materially move the broader market.

Analysis

Nanobiotix presented Part 1 data from its randomized Phase 2 CONVERGE study at the 2026 ESTRO meeting, advancing clinical visibility for JNJ-1900 (NBTXR3). The update is tied to a Johnson & Johnson-sponsored trial and underscores continued development of the nanoparticle-based cancer therapy. The release is positive but early-stage and unlikely to materially move the broader market.